Chryslaine Rodríguez-Tanty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chryslaine Rodríguez-Tanty has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Marquiza Sablón-Carrazana
Centro de Neurociencias de Cuba, La Habana 11600, Cuba
3 shared publications - Alberto Bencomo-Martínez
Departamento de Farmacología, Centro de Neurociencias de Cuba, Avenida Independencia 8126, La Habana 11600, Cuba
2 shared publications - Ana Gabriela Hernández-Puga
Centro de Investigación Biomédica Avanzada, Facultad de Medicina, Universidad Autónoma de Querétaro, Santiago de Querétaro 76140, Mexico
2 shared publications - Fausto Sanabria Romero
Departamento de Neurobiología del Desarrollo y Neurofisiología, Instituto de Neurobiología-UNAM Campus Juriquilla, Boulevard Juriquilla 3001, Juriquilla 76230, Querétaro, Mexico
2 shared publications - Humberto Martínez-Orozco
Departamento de Neurobiología del desarrollo y neurofisiología, Instituto de Neurobiología, Universidad Nacional Autónoma de México (UNAM), Querétaro, Mexico
2 shared publications - Isaac Vargas-Rodríguez
Departamento de Neurobiología del Desarrollo y Neurofisiología, Instituto de Neurobiología-UNAM Campus Juriquilla, Boulevard Juriquilla 3001, Juriquilla 76230, Querétaro, Mexico
2 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1301
CNEURO-201, an Anti-amyloidogenic Agent and σ1-Receptor Agonist, Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology
The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other remains related to this pathology remain to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg−1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system, and glial cell activation-related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in the redox system. Our outcomes reinforced the potential of CN in treating AD by acting on multiple pathways altered in this disease.
- 3 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (3) , 1301
Open AccessCNEURO-201, an Anti-amyloidogenic Agent and σ1-Receptor Agonist, Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology
The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other remains related to this pathology remain to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg−1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system, and glial cell activation-related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in the redox system. Our outcomes reinforced the potential of CN in treating AD by acting on multiple pathways altered in this disease.
- Open Access
- 18 December 2024
- Published by MDPI AG in Preprints.org
CNEURO-201, an Anti-Amyloidogenic Agent and σ1-Receptor Agonist Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology
The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits a great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other pathways related to this pathology remains to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg-1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system and glial cell activation related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques, but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in redox system. Our outcomes reinforced the potential of CN to treat AD by acting on multiple pathways altered in this disease.
- 18 December 2024
- Published by MDPI AG in Preprints.org
Open AccessCNEURO-201, an Anti-Amyloidogenic Agent and σ1-Receptor Agonist Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology
The complexity of Alzheimer’s disease (AD) pathophysiology represents a significant challenge in the development of effective therapeutic agents for its treatment. CNEURO-201 (CN, also Amylovis-201) is a novel pharmaceutical agent with dual activity as an anti-amyloid-β (Aβ) agent and σ1 receptor agonist. CN exhibits a great efficacy at very low doses, delaying cognitive impairment and alleviating Aβ load in animal models of AD. However, CN functions on other pathways related to this pathology remains to be investigated. The present study sought to evaluate the effects of CN treatment at a dosage of 0.1 mg kg-1 (p.o) over an eight-week period in the 3xTg-AD mouse model. In silico studies, as well as biochemical and immunofluorescence assays, were conducted on brain tissue to investigate the CN effects on acetylcholine metabolism, redox system and glial cell activation related biomarkers in brain regions that are relevant for memory. The results demonstrated that CN effectively rescues cognitive impairment of 3xTg-AD mice by influencing glial activity to reduce existing Aβ plaques, but also modulating acetylcholine metabolism and the enzymatic response of proteins involved in redox system. Our outcomes reinforced the potential of CN to treat AD by acting on multiple pathways altered in this disease.
- Open Access
- 20 June 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (10) , 4345-4359
Amylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein
- 20 June 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 14 (10) , 4345-4359
Open AccessAmylovis-201 is a new dual-target ligand, acting as an anti-amyloidogenic compound and a potent agonist of the σ1 chaperone protein
- Open Access
- 1 November 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 14 (1) , 26
Magnetic Nanoparticles Conjugated to Amylovis® as Contrast Agents, Synthesis and In Silico Evaluation
Iron oxide nanoparticles (IONPs) have high relativity for Magnetic Resonance Imaging (MRI) and have shown a long half-life which can covalently bind with drugs and antibodies that can be used for increased contrast while imaging with MRI. IONPs are approved by the U.S Food and Drug Administration to be used as a contrast agent for MRI in vivo. The Cuban Neuroscience Center has developed a new family of naphthalene derivative compounds called Amylovis® to be used to diagnose and treatment of Alzheimer’s disease (AD). The goal of this work is to synthesize IONPs with different coatings to be conjugated to Amylovis® as contrast agents for MRI. Coprecipitation method was employed to obtain the magnetic nuclei, and two synthesis methodologies were performed to coat the IONPs (post-synthesis or in situ). The different coatings used were the following: (3-aminopropyl)triethoxysilane (APTES), dicarboxylic polyethyleneglycol, galic acid, polyacrylic acid and citrate. Carbodiimide method was used as synthetic protocol to conjugate the Amylovis® moiety to different coatings. The nanoparticles were characterized by DRX, FT-IR, Electrophoretic Light Scattering (ELS) and Dynamic Light Scattering (DLS). Moreover, the stability of nanoparticles in water was evaluated using a sedimentation curve. In order to determine the potential interaction of nanosystems with the beta amyloid peptides, a molecular docking was carried out. The theoretical study showed that coatings do not affect the interaction of Amylovis® with the receptor, and the new polar groups incorporated increased the affinity to receptor.
- 1 November 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 14 (1) , 26
Open AccessMagnetic Nanoparticles Conjugated to Amylovis® as Contrast Agents, Synthesis and In Silico Evaluation
Iron oxide nanoparticles (IONPs) have high relativity for Magnetic Resonance Imaging (MRI) and have shown a long half-life which can covalently bind with drugs and antibodies that can be used for increased contrast while imaging with MRI. IONPs are approved by the U.S Food and Drug Administration to be used as a contrast agent for MRI in vivo. The Cuban Neuroscience Center has developed a new family of naphthalene derivative compounds called Amylovis® to be used to diagnose and treatment of Alzheimer’s disease (AD). The goal of this work is to synthesize IONPs with different coatings to be conjugated to Amylovis® as contrast agents for MRI. Coprecipitation method was employed to obtain the magnetic nuclei, and two synthesis methodologies were performed to coat the IONPs (post-synthesis or in situ). The different coatings used were the following: (3-aminopropyl)triethoxysilane (APTES), dicarboxylic polyethyleneglycol, galic acid, polyacrylic acid and citrate. Carbodiimide method was used as synthetic protocol to conjugate the Amylovis® moiety to different coatings. The nanoparticles were characterized by DRX, FT-IR, Electrophoretic Light Scattering (ELS) and Dynamic Light Scattering (DLS). Moreover, the stability of nanoparticles in water was evaluated using a sedimentation curve. In order to determine the potential interaction of nanosystems with the beta amyloid peptides, a molecular docking was carried out. The theoretical study showed that coatings do not affect the interaction of Amylovis® with the receptor, and the new polar groups incorporated increased the affinity to receptor.
- 1 October 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (20) , 115700
A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer's disease
- 1 October 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 28 (20) , 115700
A new naphthalene derivative with anti-amyloidogenic activity as potential therapeutic agent for Alzheimer's disease
- Open Access
- 1 September 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (9) , e0135292
Drug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid Structures
The increasing prevalence of conformational diseases, including Alzheimer's disease, type 2 Diabetes Mellitus and Cancer, poses a global challenge at many different levels. It has devastating effects on the sufferers as well as a tremendous economic impact on families and the health system. In this work, we apply a cross-functional approach that combines ideas, concepts and technologies from several disciplines in order to study, in silico and in vitro, the role of a novel chemical chaperones family (NCHCHF) in processes of protein aggregation in conformational diseases. Given that Serum Albumin (SA) is the most abundant protein in the blood of mammals, and Bovine Serum Albumin (BSA) is an off-the-shelf protein available in most labs around the world, we compared the ligandability of BSA:NCHCHF with the interaction sites in the Human Islet Amyloid Polypeptide (hIAPP):NCHCHF, and in the amyloid pharmacophore fragments (Aβ17–42 and Aβ16–21):NCHCHF. We posit that the merging of this interaction sites is a meta-structure of pharmacophore which allows the development of chaperones that can prevent protein aggregation at various states from: stabilizing the native state to destabilizing oligomeric state and protofilament. Furthermore to stabilize fibrillar structures, thus decreasing the amount of toxic oligomers in solution, as is the case with the NCHCHF. The paper demonstrates how a set of NCHCHF can be used for studying and potentially treating the various physiopathological stages of a conformational disease. For instance, when dealing with an acute phase of cytotoxicity, what is needed is the recruitment of cytotoxic oligomers, thus chaperone F, which accelerates fiber formation, would be very useful; whereas in a chronic stage it is better to have chaperones A, B, C, and D, which stabilize the native and fibril structures halting self-catalysis and the creation of cytotoxic oligomers as a consequence of fiber formation. Furthermore, all the chaperones are able to protect and recondition the cerebellar granule cells (CGC) from the cytotoxicity produced by the hIAPP20–29 fragment or by a low potassium medium, regardless of their capacity for accelerating or inhibiting in vitro formation of fibers. In vivo animal experiments are required to study the impact of chemical chaperones in cognitive and metabolic syndromes.
- 1 September 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (9) , e0135292
Open AccessDrug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid Structures
The increasing prevalence of conformational diseases, including Alzheimer's disease, type 2 Diabetes Mellitus and Cancer, poses a global challenge at many different levels. It has devastating effects on the sufferers as well as a tremendous economic impact on families and the health system. In this work, we apply a cross-functional approach that combines ideas, concepts and technologies from several disciplines in order to study, in silico and in vitro, the role of a novel chemical chaperones family (NCHCHF) in processes of protein aggregation in conformational diseases. Given that Serum Albumin (SA) is the most abundant protein in the blood of mammals, and Bovine Serum Albumin (BSA) is an off-the-shelf protein available in most labs around the world, we compared the ligandability of BSA:NCHCHF with the interaction sites in the Human Islet Amyloid Polypeptide (hIAPP):NCHCHF, and in the amyloid pharmacophore fragments (Aβ17–42 and Aβ16–21):NCHCHF. We posit that the merging of this interaction sites is a meta-structure of pharmacophore which allows the development of chaperones that can prevent protein aggregation at various states from: stabilizing the native state to destabilizing oligomeric state and protofilament. Furthermore to stabilize fibrillar structures, thus decreasing the amount of toxic oligomers in solution, as is the case with the NCHCHF. The paper demonstrates how a set of NCHCHF can be used for studying and potentially treating the various physiopathological stages of a conformational disease. For instance, when dealing with an acute phase of cytotoxicity, what is needed is the recruitment of cytotoxic oligomers, thus chaperone F, which accelerates fiber formation, would be very useful; whereas in a chronic stage it is better to have chaperones A, B, C, and D, which stabilize the native and fibril structures halting self-catalysis and the creation of cytotoxic oligomers as a consequence of fiber formation. Furthermore, all the chaperones are able to protect and recondition the cerebellar granule cells (CGC) from the cytotoxicity produced by the hIAPP20–29 fragment or by a low potassium medium, regardless of their capacity for accelerating or inhibiting in vitro formation of fibers. In vivo animal experiments are required to study the impact of chemical chaperones in cognitive and metabolic syndromes.
- 1 October 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 336 (3) , 983-986
Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus
- 1 October 2005
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 336 (3) , 983-986
Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus
- 1 January 2005
- Published by Taylor & Francis in Preparative Biochemistry & Biotechnology
- Vol. 35 (1) , 1-15
Non‐Enzymatic In Vitro DNA Labeling and Label Immunoquantification
In the present work, a label immunoquantification procedure was developed in order to determine the number of markers introduced into DNA. A non‐enzymatic, in vitro labeling method for introducing the p‐bromobenzoyl radical (label), through transamination and acylation reactions of the cytidine nucleotides in calf thymus DNA, was carried out. Three spacer arms with different lengths were used for separating the label from the nucleotide and three labeled DNA were obtained. Anti‐p‐bromobenzoyl chicken IgY polyclonal antibodies were obtained. The antibodies detected the label, into three‐labeled DNA, with different sensitivities, in relation to spacer arm length used. About 3–11 labels per 4 × 106 bases into thermally denatured DNA were immunoquantified.
- 1 January 2005
- Published by Taylor & Francis in Preparative Biochemistry & Biotechnology
- Vol. 35 (1) , 1-15
Non‐Enzymatic In Vitro DNA Labeling and Label Immunoquantification
In the present work, a label immunoquantification procedure was developed in order to determine the number of markers introduced into DNA. A non‐enzymatic, in vitro labeling method for introducing the p‐bromobenzoyl radical (label), through transamination and acylation reactions of the cytidine nucleotides in calf thymus DNA, was carried out. Three spacer arms with different lengths were used for separating the label from the nucleotide and three labeled DNA were obtained. Anti‐p‐bromobenzoyl chicken IgY polyclonal antibodies were obtained. The antibodies detected the label, into three‐labeled DNA, with different sensitivities, in relation to spacer arm length used. About 3–11 labels per 4 × 106 bases into thermally denatured DNA were immunoquantified.